Molecular diagnosis of prostate cancer: Topical issues

Cover Page

Cite item

Full Text

Abstract

Prostate cancer (PC) is the second most common cancer and the fifth highest malignancy mortality rate in men worldwide. Although PC is detectable in 15-20% of men during life, its death risk is only about 3%. This means that not all PC cases require the same management tactics. The given review analyzes the current investigations searching for molecular biological markers to predict the course of PC and to choose its treatment policy, including that in the development of resistance to androgen-deprivation therapy.

About the authors

E. N. Knyazev

P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia; 3, Second Botkinsky Pr., Moscow 125284

Russian Federation

K. A. Fomicheva

P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia; 3, Second Botkinsky Pr., Moscow 125284

Russian Federation

K. M. Nyushko

P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia; 3, Second Botkinsky Pr., Moscow 125284

Author for correspondence.
Email: kirandja@yandex.ru
Russian Federation

A. D. Kaprin

P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia; 3, Second Botkinsky Pr., Moscow 125284

Russian Federation

B. Ya. Alekseev

P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia; 3, Second Botkinsky Pr., Moscow 125284

Russian Federation

M. Yu. Shkurnikov

P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia; 3, Second Botkinsky Pr., Moscow 125284

Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 36986 от  21.07.2009.